Drug Trial Radar · NCT02992743
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
Last checked: Nov 20, 2026Latest source record: Apr 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Dec 6, 2016
Primary completion
Nov 1, 2021
Study completion Mar 22, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate safety and efficacy of Letetresgene autoleucel (GSK3377794) in participants with advanced myxoid/round cell liposarcoma or high-grade myxoid liposarcoma.
Conditions
- Neoplasms
Interventions
letetresgene autoleucel (GSK3377794)Drug
Letetresgene autoleucel (GSK3377794) as an IV infusion.
CyclophosphamideDrug
Cyclophosphamide will be used as a lymphodepleting chemotherapy.
FludarabineDrug
Fludarabine will be used as a lymphodepleting chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator AssessmentTime frame: Up to 24 months
- Best Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator AssessmentTime frame: Up to 24 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Ann Arbor, Michigan
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
New York, New York
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.